Author

Jonathan Dabora

Observed name: Dabora, Jonathan

Observed institution: Takeda (Japan)

OpenAlex ID: A5042001822

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States

2023 · Larysa Sanchez, Ajai Chari, et al. · Journal of Managed Care & Specialty Pharmacy · 3

Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States

2024 · Sikander Ailawadhi, Mu Cheng, et al. · Journal of Managed Care & Specialty Pharmacy · 1

Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone

2024 · Karthik Ramasamy, Nizar J. Bahlis, et al. · Haematologica · 1

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

2023 · Maral DerSarkissian, Holly Cranmer, et al. · Hematology · 1

P-190: A systematic literature review and indirect treatment comparison among randomized clinical trials to estimate the relative efficacy of treatments for relapsed/refractory multiple myeloma

2021 · Rachel Bhak, Holly Cranmer, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 6

Citation count: 6

H-index: 1

I10-index: